Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2020 / Article

Research Article | Open Access

Volume 2020 |Article ID 5267684 | https://doi.org/10.1155/2020/5267684

Youfa Qin, Yongkun Zhu, Xiaoyan Xue, Guanghui Zhou, Huibo Li, Jian Wang, "An In Vitro Study for Evaluating Permeability and Metabolism of Kurarinone", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 5267684, 11 pages, 2020. https://doi.org/10.1155/2020/5267684

An In Vitro Study for Evaluating Permeability and Metabolism of Kurarinone

Academic Editor: Kenji Watanabe
Received28 Oct 2019
Accepted03 Sep 2020
Published14 Sep 2020


Kurarinone is a major component found in the dried roots of Sophora flavescens Ait. that participates in vital pharmacological activities. Recombinant CYP450 supersomes and liver microsomes were used to study the metabolic profiles of kurarinone and its inhibitory actions against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes. 100 μM of kurarinone strongly inhibited more than 90% of UGT1A1, UGT1A6, CYP1A2, and CYP2C9. CYP1A2 and CYP2D6 played important roles in catalyzing the biotransformation of kurarinone. Moreover, metabolism of kurarinone considerably differs among species, and metabolic characteristics were similar between monkey and human. Kurarinone demonstrated moderate permeability at values of pH 4.0 and 7.4. Our findings offer a clearer idea to understand the pharmacological and toxicological mechanisms of kurarinone.

1. Introduction

The dry root of Sophora flavescens Ait. has been an important species in traditional Chinese medicine since the Qin and Han dynasties. S. flavescens has been documented in editions of the Pharmacopoeia of the People’s Republic of China since 1977. Novel dosage forms in terms of tablets, capsules, and injections were developed, recently [1]. Currently, S. flavescens is widely used to treat dysentery [1], fever [2], skin and mucosal ulcers [3], diarrhea [4], and reduce edema by inducing diuresis [5]. Besides, S. flavescens is known to exhibit varied pharmacological properties including antitumor [6, 7], anti-inflammatory [8], and antibacterial [9, 10] activities. Kurarinone (showed in Figure 1) is a major constituent of S. flavescens with the content ranging from 4.79 mg/g to 16.07 mg/g [11]. Kurarinone exhibits antitumor [12, 13], anti-inflammatory [8], antioveractive bladder [14], antioxidant [15], and antityrosinase [16] activities. It also induced remarkable cytotoxicity in primary rat hepatocytes and HL-7702 cells [17, 18].

Cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) are important phase-I and -? drug-metabolizing enzymes that actively participate in the metabolism of more than 90% of currently available drugs [19]. Inhibition or induction of CYPs or UGTs might cause potential drug-drug interactions (DDIs). S. flavescens induces CYP3A expression by activating the pregnane X receptor (PXR) [20]. S. flavescens extract has been found to reduce blood theophylline concentration in rats by inducing hepatic CYPs including CYP1A2, CYP2B, CYP2E1, and CYP3A [21]. Several other studies reported that S. flavescens extract dose-dependently inhibited human hepatic CYP2C8, CYP2C9, CYP1A2, CYP2C19, CYP2B6, and CYP3A4 [2, 22, 23]. Such varying experimental outcomes may be due to the complexity of S. flavescens extracts. Although kurarinone is a marker compound of S. flavescens, the interactions between former and CYPs or UGTs are yet to be investigated earlier.

Currently, the parallel artificial membrane permeation assay (PAMPA) is used as a rapid in vitro assay of passive biomembrane permeation in the drug discovery stage [24]. This technique was developed by Kansy et al. [25] and had been originally established to rapidly predict passive permeability through the gastrointestinal tract [26]. Nevertheless, the permeability of kurarinone has not yet been reported.

In this study, the liver microsomes and recombinant human supersomes were used to explore the interaction of kurarinone and UGTs or CYPs, which would contribute to its safe clinical usage and minimize the occurrence of DDIs.

2. Materials and Methods

2.1. Chemicals and Reagents

Kurarinone (>98%) was purchased from BioBioPha Co., Ltd. (Kunming, China). Glucose-6-phosphate, glucose-6-phosphate dehydrogenase, NADP+, D-glucose-6-phosphate, Tris-HCl, 7-hydroxycoumarin, 4-methylumbelliferone (4-MU), 4-methylumbelliferone-β-D-glucuronide, uridine 5′-diphosphoglucuronic acid (UDPGA; trisodium salt), phenacetin, diclofenac, dextromethorphan, chlorzoxazone, testosterone, (S)-mephenytoin, sulfaphenazole, quinidine, clomethiazole, furafylline, ketoconazole, and omeprazole were purchased from Sigma Aldrich (St. Louis, MO, USA). Metabolites of the probe substrates including 6-hydroxylated chlorzoxazone (2E1), O-deethylated phenacetin (CYP1A2), 4′-hydroxylated diclofenac (2C9), 4′-hydroxylated (S)-mephenytoin (2C19), O-demethylated dextromethorphan (2D6), and 6β-hydroxylated testosterone (3A4) were provided from the Research Institute for Liver Disease Co., Ltd. (Shanghai, China). Pooled liver microsomes from humans (HLMs), monkeys (MLMs), rabbits (RAMs), rats (RLMs), mouse (MOMs), dogs (DLMs), and minipigs (PLMs) were provided by the Research Institute for Liver Disease Co., Ltd. (Shanghai, China). Recombinant human supersomes (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, CYP1A2, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP2C19) were obtained from BD Gentest Corp. (Woburn, MA, USA).

2.2. Analytical Instruments and Conditions

The HPLC analysis was performed using the Shimadzu LC-20AB system (Shimadzu, Kyoto, Japan) equipped with the Hypersil BDS C18 column (Dalian Elite Analytical Instruments Co., Dalian, China; 4.6 × 150 mm, 5 μm). The mobile phase consisted of (A) water containing 0.1% formic acid and (B) acetonitrile with a flow rate of 1.0 mL/min. A gradient elution program was performed: 0.0–11.0 min, 40%–60% B; 11.0-12.00 min, 60%–90% B; 12.0–15.0 min, 90% B; 15.0–16.0 min, 90%–40% B; and 16.0–22.0 min, 40% B. Kurarinone and its metabolites were detected at 280 nm.

2.3. In Vitro Incubation Systems in Liver Microsomes or Recombinant CYP Supersomes

Samples were prepared in a total volume of 200 μL, containing 0.3 mg/mL protein in human liver microsomes or 15 nM protein in recombinant human supersomes, probe substrates or 50 μM kurarinone, 10 mM MgCl2, 10 mM glucose-6-phosphate, and 1 unit/mL of glucose-6-phosphate dehydrogenase. The reactions were activated by adding NADPH following preincubation at 37°C for 5 min. The reactions were maintained at 37°C for 1 h and terminated by adding 200 μL ice-cold acetonitrile. The supernatant (10 μL) collected from the samples that were centrifuged (20,000 g, 20 min, 4°C) was injected into the HPLC system for analysis. Control incubations devoid of NADPH or kurarinone were performed parallelly to ensure that the produced metabolites were NADPH- or kurarinone-dependent.

2.4. Inhibitory Effect of CYP Activities by Kurarinone

RLMs were used to assess the inhibitory effects of kurarinone (100 μM) on six different human isoforms (CYP1A2, CYP2C9, CYP2D6, CYP2E1, CYP3A4, and CYP2C19). The probe substrates used in this experiment were 40 μM phenacetin for CYP1A2, 10 μM diclofenac for CYP2C9, 25 μM dextromethorphan for CYP2D6, 120 μM chlorzoxazone for CYP2E1, 35 μM testosterone for CYP3A4, and 20 μM (S)-mephenytoin for CYP2C9 as described earlier [27]. The reaction system has been described in Section 2.3. Kinetic parameters including IC50 and Ki were determined and analyzed for CYP isoforms whose activities were strongly inhibited by more than 90%. Dixon and Lineweaver–Burk plots were formed to confirm the reversible inhibition type, and a second plot of slopes from the Lineweaver–Burk plot over the concentrations of kurarinone was used to estimate the Ki value. All incubations were performed in triplicates, and mean values were used for analysis.

2.5. Inhibition of 4-MU Glucuronidation Assay

4-MU, a nonspecific probe substrate for UGT isoforms, was used to explore the inhibition of UGT isoforms by kurarinone. The mixture (200 μL total volume) contained recombinant UGTs (final concentrations: 0.125, 0.05, 0.025, 0.05, 0.025, 0.05, 0.05, 0.25, 0.05, and 0.2 mg/mL for UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, and UGT2B15, respectively), 5 mM UDPGA, 5 mM MgCl2, 50 mM Tris-HCl buffer (pH 7.4), and 4-MU in the absence or presence of various concentrations of kurarinone. The concentrations of 4-MU were as follows: 110 μM for UGT1A1 and UGT1A6, 1200 μM for UGT1A3 and UGT2B4, 15 μM for UGT1A7, 750 μM for UGT1A8, 30 μM for UGT1A9, 80 μM for UGT1A10, 350 μM for UGT2B7, 250 μM for UGT2B15, and 2000 μM for UGT2B17. Kurarinone was dissolved in methanol, and the final concentration of methanol was 0.5% (). Reactions were initiated by adding UDPGA, and incubations were carried out at 37°C in a shaking waterbath for 60 min. The reactions were terminated by addition of 200 μL of ice-cold acetonitrile containing 7-hydroxycoumarin (100 μM) as the internal standard. The incubation mixture was then centrifuged at 20,000 × for 20 min to obtain the supernatant, and an aliquot of supernatant (20 μL) was transferred to an autoinjector vial for HPLC analysis.

2.6. Reaction Phenotyping Assays

Recombinant human supersomes (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and CYP4F2) were used to valuate the CYP enzyme participating in kurarinone metabolite formation. The incubation for each CYP isoform was carried out as described in Section 2.3. Kurarinone (20 μM) was incubated with each of the recombinant CYPs (15 nM) at 37°C for 30 min, and plausible metabolites were monitored.

2.7. Chemical Inhibition Study

Chemical inhibition studies were carried out by adding various human CYP inhibitors to the incubation mixture of kurarinone (20 μM) prior to the addition of the NADPH-generating system. HLMs were utilized as metabolic enzymes. The period of incubation and conditions are detailed in Section 2.3.

2.8. Kinetics Study

Various concentrations of kurarinone (1–200 μM) were incubated with RLMs, MLMs, PLMs, RAMs, CYP1A2, and CYP2D6 to estimate kinetic parameters. The rest of the other conditions remained the same as described in Section 2.3. Preliminary experiments evidenced that the formations of metabolites occurred in a linear range of reaction time and concentrations of microsomes. The apparent Km and values were calculated from nonlinear regression analysis of experimental data according to the Michaelis–Menten equation, and the results were represented graphically by Eadie–Hofstee plots. All incubations were carried out as triplicate independent experiments, and kinetic constants were recorded as mean ± SD.

2.9. Prediction of In Vivo Hepatic Clearance

The following equations were utilized to predict the in vivo hepatic clearance of kurarinone in humans and rats [28].where the SF (scaling factor) represents the milligrams of microsomal protein per gram of the liver multiplied by the grams of liver weight; CLint is the intrinsic metabolic clearance; CLH is hepatic clearance; fu is the free fraction in the blood (no data were available for kurarinone; thus, fu was arbitrarily proposed to be 1); and QH is the hepatic blood flow. The CLH of kurarinone was calculated using equations (1)–(3). The physiological parameters for calculating the intrinsic clearance in rats and humans are described as follows: the amounts of microsomal protein were 44.8 mg and 48.8 mg of protein/g of the liver; the liver weight per kilogram of body weight values were 40 g and 25.7 g; and the liver blood flow values were 55.2 mL/min/kg and 20.7 mL/min/kg, respectively [29].

2.10. Molecular Docking

Molecular docking analysis was performed to further assess the molecular mechanism of interaction between kurarinone and CYPs. The X-ray structures of CYP 1A2 (PDB code 2HI4), 2C9 (PDB code 3QM4), and 2D6 (PDB code 4WNU) were obtained from RCSB Protein Databank (http://rcsb.org/). Molecular docking evaluations were performed with AutoDock 4.02. Schrodinger Maestro software was utilized for graphic display. The protein structures were prepared through ProteinPrep wizard within Schrodinger package, and the energy minimization was completed through the external Tripos forcefield. The cluster analysis with AutoDock results was performed to determine best poses of kurarinone within investigated CYP sites.

2.11. PAMPA Permeability Study

The PAMPA method was used to measure the membrane permeability values, as described by Singh et al. in an earlier study [30]. Drug samples were dissolved in DMSO and then diluted to 10 mM concentrations as a stock solution. 300 μL diluted drugs solution was filled in the PAMPA plate as the “donor” wells, and the 96-well filter plate with a synthetic phospholipid membrane was then placed on the donor wells. The “acceptor” wells were filled with 200 μl of buffer solution, and the PAMPA instruments were incubated at room temperature for 5 h. Kurarinone permeability was assessed in quadruplicate at pH 4.0 and 7.4. Naproxen was taken as a high permeability marker and furosemide as a low permeability marker. At the end of the incubation, kurarinone and the marker compounds in the donor and acceptor wells were determined by HPLC, and permeability was calculated.

3. Results

3.1. Metabolic Profiling of Kurarinone in Different Liver Microsomes

After kurarinone (20 μM) was incubated for one hour with different liver microsomes such as HLMs, RLMs, RAMs, PLMs, MOMs, MLMs, and DLMs, HPLC was utilized to confirm the biotransformation of kurarinone. As showed in Figure 2, a new peak () was detected at 6.77 min compared with that of the control group, which was inferred as the main metabolite of kurarinone owing to its high peak area for all species. The formation of metabolite was time-, NADPH-, and microsome-dependent.

3.2. Inhibitory Effects of Kurarinone against UGT and CYP Activities

100 μM kurarinone inhibited the activities of UGT1A1, UGT1A6, CYP1A2, and CYP2C9 by more than 90%. Inhibition kinetic parameters of UGT1A1 and CYP1A2 were established. Kurarinone displayed concentration-dependent inhibitions against UGT1A1 and CYP1A2 with IC50 values of 13.64 μM and 10.02 μM, respectively (Figures 3(a) and 4(a)). Dixon (Figures 3(b), and 4(b)) and Lineweaver–Burk plots (Figures 3(c), and 4(c)) demonstrated that UGT1A1 and CYP1A2 inhibition by kurarinone was fitted well by noncompetitive and competitive inhibition, respectively. The Ki values were calculated to be 13.04 μM and 8.13 μM for UGT1A1 and CYP1A2 by a second plot of the slopes from the Lineweaver–Burk plots versus kurarinone concentrations (Figures 3(d), and 4(d)). Kurarinone exhibited competitive inhibition against CYP1A2 and noncompetitive inhibition against UGT1A1.

3.3. CYP Isoforms Involved in Catalyzing the Formation of Metabolite

After kurarinone was incubated with different liver microsomes, its main metabolite () was determined. Kurarinone was incubated with 13 cDNA-expressed human CYP isoforms for confirming the CYP isoform involved in metabolizing kurarinone. Figure 5 indicates that CYP1A2 and CYP2D6 played a significant role in catalyzing the formation of , whereas the other enzymes hardly contributed in metabolizing kurarinone.

The results were confirmed through the chemical inhibition study. Kurarinone was incubated with selective chemical inhibitors of the eight CYP isoforms in HLMs, and the results showed that furafylline (CYP1A2 inhibitor) and quinidine (CYP2D6 inhibitor) remarkably inhibited the formation of compared with other CYP isoform inhibitors (Figure 6).

3.4. Enzyme Kinetics Study

As shown in Figure 7, the metabolic profiles of kurarinone (1–200 μM) in RLMs, MLMs, PLMs, HLMs, CYP1A2, and CYP2D6 exhibited typical monophasic Michaelis–Menten kinetics, which were further confirmed by Eadie–Hofstee plots. The kinetic parameters (Km, , and CLint) were calculated using data and are summarized in Table 1.


Km9.45 ± 2.1113.76 ± 3.0921.02 ± 3.4221.96 ± 4.9349.91 ± 7.9118.08 ± 3.91
2.45 ± 0.252.78 ± 0.364.83 ± 0.141.56 ± 0.248.46 ± 0.743.34 ± 0.19

aKm, , and CLint are expressed in units of μM, μmol·min−1·nmol−1 CYP, and mL·min−1·pmol−1 CYP, respectively. bKm, , and CLint are expressed in units of μM, nmol·min−1·mg−1 protein, and mL·min−1·mg−1 protein, respectively.
3.5. Prediction of In Vivo Hepatic Clearance in Human and Rat

CLH was calculated using the kinetic parameters of generated from nonlinear regression in HLMs and RLMs, and the results were 16.82 mL/min/kg and 46.01 mL/min/kg body weight for humans and rats. The percentages of CLH versus hepatic blood flow (QH) values for human and rat were 81.27% and 83.35%, respectively.

3.6. Molecular Modeling

CYP2D6 and CYP1A2 were observed to be two important metabolic enzymes catalyzing the biotransformation of kurarinone, while kurarinone strongly inhibited the activities of CYP2C9 and CYP1A2. Molecular docking evaluations were performed to further verify the interaction between kurarinone and CYP2D6, CYP2C9, and CYP1A2 at a molecular level. Kurarinone was found to bound within the binding pockets of CYP1A2, CYP2C9, and CYP2D6, forming H-bonds with Asn312 and Asp320 of CYP1A2 (Figure 8(a)), Asp301 of CYP2C9 (Figure 8(b)), and Gln244 and Ser304 of CYP2D6 (Figure 8(c)), separately. Hydrophobic residues surrounding kurarinone were also observed within the investigated CYPs, including Ile117, Phe125, Phe319, Leu382, Ile386, and Leu497 within the CYP1A2 pocket, Leu208, Leu213, Leu248, Ile297, and Leu484 within the CYP2C9 pocket and Phe120, Leu121, Leu208, Phe243, Phe247, Phe248, and Ile297 within the CYP2D6 pocket, respectively.

3.7. PAMPA Permeability of Kurarinone

Drugs are primarily known to be absorbed in the small intestines, wherein the pH may vary from acidic to neutral and slightly basic. In this study, the PAMPA assay was carried out at pH 4.0 and 7.4, respectively. The PAMPA permeability results of kurarinone and permeability markers are showed in Table 2. Kurarinone exhibited moderate permeability at pH 4.0 and 7.4.

CompoundPe × 10−6 (cm/s)
pH = 4pH = 7

Naproxen (high permeability marker)5.38 ± 1.365.76 ± 1.75
Furosemide (low permeability marker)0.06 ± 0.010.07 ± 0.02
Kurarinone3.87 ± 1.392.14 ± 0.82

4. Discussion

Owing to its various pharmacological activities, kurarinone will be coadministered with other drugs. Hence, assessment of potential DDIs is an essential process in the clinical development of kurarinone. Both Food and Drug Administration (FDA) and European Medicines Agency (EMA) affirmed that Cmax/Ki ratio was calculated as an indicator of in vivo DDI potential. The interaction likely occurred if the Cmax/Ki value of the inhibitor is greater than 1, possibly occurred if the ratio is between 0.1 and 1, and unlikely occurred if below 0.1 [31]. Kurarinone potently inhibited CYP1A2 with the Ki value of 8.13 μM in RLMs. The Cmax value of kurarinone in rats was recorded to be 1668.01 ng/mL [32], and Cmax/Ki value was calculated to be 0.46, indicating that the in vivo adverse effects possibly occur due to the Cmax/Ki value of kurarinone against CYP1A2. Thus, potential metabolism-based DDIs might occur during coadministration of kurarinone with other CYP1A2 substrate such as tizanidine [33]. Nevertheless, it is noteworthy that S. flavescens extracts could induce CYP1A, CYP2B1/2, CYP2C11, and CYP3A in rats and mice [22]. The complexity of S. flavescens extracts may be the reason for varying experimental results, and while the alkaloids matrine and oxymatrine participated in inducting CYP isoforms [3]. Hence, clinicians should be aware of the in vivo concentration alterations of CYP1A2-metabolized substrates when their patients are administered S. flavescens with a high content of kurarinone.

Reaction phenotyping assays and chemical inhibition study evidenced that CYP1A2 and CYP2D6 play a significant role in catalyzing the formation of , whereas other enzymes exhibited limited ability to metabolize kurarinone. If kurarinone was coadministered with a CYP1A2 or CYP2D6 inhibitor, the CYP inhibition might likely amplify the blood concentration of kurarinone and lead to adverse effects.

Animals are often used as a model to predict kinetics and toxicity in humans. As we know, CYPs are classified into distinct subfamilies on the basis of amino acid sequence identity. A high degree of sequence identity does not necessarily indicate similar catalytic specificity, and a single amino acid substitution may even result in a change in substrate specificity. Therefore, the substantial differences in CYPs among various species may cause varying drug metabolism across species [34]. In the current experiments, enzyme kinetic studies were performed to further assess species difference. Differences in Km value have shown significance to comprehend the basis of species-related differences in P450-catalyzed drug oxidation reactions [35]. Similar Km values among various species reflect equivalent binding affinities toward the metabolic site and indicate species similarities [36]. The comparable Km values for the formation of in MLMs and HLMs in this study evidenced similar CYPs affinity in these two mammals. Monkeys and humans have a common ancestor since approximately 25 million years ago. Monkeys are genetically and physiologically similar to humans and are therefore the most extensively used nonhuman primate in basic and applied biomedical research [37]. Owing to higher values, the CLint values in MLMs, RLMs, and PLMs were found to be much higher than those in HLMs, while all the differences were statistically significant, evidencing that these liver preparations transformed kurarinone more efficiently than that in HLMs. The Km, , and CLint values for the oxidative metabolism of kurarinone in CYP2D6 and CYP1A2 were similar. The Km values were found to be much higher for kurarinone metabolism in liver microsomes than those in CYP2D6 and CYP1A2, which may be due to the nonspecific binding of kurarinone to microsomal material. The kinetic constant values of single CYP in cDNA expression systems and multiple CYPs in liver microsomal systems are incomparable [38].

Compounds can be classified into high-clearance (>70% liver blood flow), low-clearance (<30% liver blood flow), and intermediate-clearance drugs on the base of CLH value projected from the in vitro data. Here, kurarinone was categorized as a high-clearance drug in humans and pigs. After intravenous administration of 10 mg/kg kurarinone in six rats, the t1/2 was calculated, 1.81 h [32], proving that kurarinone could be cleared quickly in vivo.

Molecular docking was performed in this study to investigate the molecular mechanism of interactions between kurarinone and CYPs. The results exhibited that kurarinone interacted with CYP1A2 (Asn312 and Asp320), CYP2C9 (Asp301), and CYP2D6 (Gln244 and Ser304) through formation of H-bonds. Asn312 and Asp320 are significant residues in the substrate and inhibitor recognition regions of CYP1A2 [39, 40]. Gln244 and Ser304 in CYP2D6 are active site residues involved in hydrogen bond formation with substrates [41].

More than 80% of orally administered drugs are absorbed into the bloodstream through passive diffusion in the small intestines. Thus, to detect the intestinal absorption and bioavailability, the passive diffusion of a drug must be comprehended. PAMPA is one of the most widely used assays to predict transcellular passive absorption in vitro models [42]. In the present study, permeability of kurarinone was evaluated at pH 4.0 and 7.4, which corresponded to conditions in the stomach, small intestine, and plasma. The permeability of kurarinone was found to be moderate, indicating that kurarinone was absorbed in the stomach and small intestine.

In this study, Kurarinone was thus evidenced to strongly inhibit UGT1A1, UGT1A6, CYP1A2, and CYP2C9, which could lead to DDIs. Kurarinone metabolism showed significant differences among species. CYP1A2 and CYP2D6 played important roles to metabolize kurarinone. The PAMPA permeability of kurarinone was moderate at both pH 4.0 and 7.4.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


This research was supported by the Medical Scientific Research Foundation of Guangdong Province (B2017033) and Traditional Chinese Medicine Bureau of Guangdong Province (20171273).


  1. L. Huang, X. Huang, J. Fang, J. Wang, and X. He, “Sophora flavescens ait.: traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine,” Journal of Ethnopharmacology, vol. 172, pp. 10–29, 2015. View at: Publisher Site | Google Scholar
  2. D. Yim, M. J. Kim, Y. Shin, S. J. Lee, J. G. Shin, and D. H. Kim, “Inhibition of cytochrome P450 activities by Sophora flavescens extract and its prenylated flavonoids in human liver microsomes,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 2673769, 10 pages, 2019. View at: Publisher Site | Google Scholar
  3. J. Yamahara, M. Mochizuki, H. Fujimura et al., “Antiulcer action of Sophora flavescens root and an active constituent. i,” Journal of Ethnopharmacology, vol. 29, no. 2, pp. 173–177, 1990. View at: Publisher Site | Google Scholar
  4. B. Yu, X. Chen, L. Jiang et al., “Acute and subchronic toxicity and the evaluation of safety pharmacology of Chinese herbal compound preparation shikuqin,” Pakistan Journal of Pharmaceutical Sciences, vol. 31, no. 6, pp. 2855–2862, 2018. View at: Google Scholar
  5. H. Ma, Q. Huang, W. Qu et al., “In vivo and in vitro anti-inflammatory effects of Sophora flavescens residues,” Journal of Ethnopharmacology, vol. 224, pp. 497–503, 2018. View at: Publisher Site | Google Scholar
  6. Y. J. Zhou, Y. J. Guo, X. L. Yang, and Z. L. Ou, “Anti-cervical cancer role of matrine, oxymatrine and Sophora flavescens alkaloid gels and its mechanism,” Journal of Cancer, vol. 9, no. 8, pp. 1357–1364, 2018. View at: Publisher Site | Google Scholar
  7. W.-C. Huang, P.-Y. Gu, L.-W. Fang, Y.-L. Huang, C.-F. Lin, and C.-J. Liou, “Sophoraflavanone g from Sophora flavescens induces apoptosis in triple-negative breast cancer cells,” Phytomedicine, vol. 61, Article ID 152852, 2019. View at: Publisher Site | Google Scholar
  8. L. Xie, W. Gong, J. Chen et al., “The flavonoid kurarinone inhibits clinical progression of EAE through inhibiting Th1 and Th17 cell differentiation and proliferation,” International Immunopharmacology, vol. 62, pp. 227–236, 2018. View at: Publisher Site | Google Scholar
  9. C. Han and J. Guo, “Antibacterial and anti-inflammatory activity of traditional Chinese herb pairs, Angelica sinensis and Sophora flavescens,” Inflammation, vol. 35, no. 3, pp. 913–919, 2012. View at: Publisher Site | Google Scholar
  10. K.-Y. Lee, S.-M. Cha, S.-M. Choi, and J.-D. Cha, “Antibacterial and synergistic effects of the n-BuOH fraction of Sophora flavescens root against oral bacteria,” Journal of Oral Science, vol. 59, no. 1, pp. 77–86, 2017. View at: Publisher Site | Google Scholar
  11. H. Y. Ma, W. S. Zhou, F. J. Chu, D. Wang, S. W. Liang, and S. Li, “HPLC fingerprint of flavonoids in Sophora flavescens and determination of five components,” Zhongguo Zhong Yao Za Zhi, vol. 38, no. 16, pp. 2690–2695, 2013. View at: Publisher Site | Google Scholar
  12. J. Yang, H. Chen, Q. Wang et al., “Inhibitory effect of kurarinone on growth of human non-small cell lung cancer: an experimental study both in vitro and in vivo studies,” Frontiers in Pharmacology, vol. 9, p. 252, 2018. View at: Publisher Site | Google Scholar
  13. W. Zhou, A. Cao, L. Wang, and D. Wu, “Kurarinone synergizes trail-induced apoptosis in gastric cancer cells,” Cell Biochemistry and Biophysics, vol. 72, no. 1, pp. 241–249, 2015. View at: Publisher Site | Google Scholar
  14. S. Lee, M. R. Chae, B.-C. Lee et al., “Urinary bladder-relaxant effect of kurarinone depending on potentiation of large-conductance Ca2+-activated K+ channels,” Molecular Pharmacology, vol. 90, no. 2, pp. 140–150, 2016. View at: Publisher Site | Google Scholar
  15. X.-L. Piao, X. S. Piao, S. W. Kim, J. H. Park, H. Y. Kim, and S.-Q. Cai, “Identification and characterization of antioxidants from Sophora flavescens,” Biological & Pharmaceutical Bulletin, vol. 29, no. 9, pp. 1911–1915, 2006. View at: Publisher Site | Google Scholar
  16. Y. B. Ryu, I. M. Westwood, N. S. Kang et al., “Kurarinol, tyrosinase inhibitor isolated from the root of Sophora flavescens,” Phytomedicine, vol. 15, no. 8, pp. 612–618, 2008. View at: Publisher Site | Google Scholar
  17. Q. Yu, N. Cheng, and X. Ni, “Identifying 2 prenylflavanones as potential hepatotoxic compounds in the ethanol extract of Sophora flavescens,” Journal of Food Science, vol. 78, no. 11, pp. T1830–T1834, 2013. View at: Publisher Site | Google Scholar
  18. X. Zhang, P. Jiang, P. Chen, and N. Cheng, “Metabolism of kurarinone by human liver microsomes and its effect on cytotoxicity,” Pharmaceutical Biology, vol. 54, no. 4, pp. 619–627, 2016. View at: Publisher Site | Google Scholar
  19. L. Wu, W. Zhong, J. Liu et al., “Human microsomal cyttrochrome P450-mediated reduction of oxysophocarpine, an active and highly toxic constituent derived from Sophora flavescens species, and its intestinal absorption and metabolism in rat,” Fitoterapia, vol. 105, pp. 26–36, 2015. View at: Publisher Site | Google Scholar
  20. L. Wang, F. Li, J. Lu et al., “The Chinese herbal medicine Sophora flavescens activates pregnane x receptor,” Drug Metabolism and Disposition, vol. 38, no. 12, pp. 2226–2231, 2010. View at: Publisher Site | Google Scholar
  21. Y.-F. Ueng, C.-C. Tsai, W.-S. Lo, and C.-H. Yun, “Induction of hepatic cytochrome P450s by the herbal medicine Sophora flavescens extract in rats: impact on the elimination of theophylline,” Drug Metabolism and Pharmacokinetics, vol. 25, no. 6, pp. 560–567, 2010. View at: Publisher Site | Google Scholar
  22. L. Chen, J. Cai, S. Wang, L. Hu, and X. Yang, “Effect of radix sophorae flavescentis on activity of CYP450 isoforms in rats,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 11, pp. 21365–21371, 2015. View at: Google Scholar
  23. Z. X. Lin, C. T. Che, S. S. Lee, R. C. Chan, P. S. Ip, and J. M. Yang, “Sophora flavescens (ku-shen) as a booster for antiretroviral therapy through cytochrome P450 3A4 inhibition,” Hong Kong Medical Journal, vol. 21, no. 7, pp. S18–S21, 2015. View at: Google Scholar
  24. K. Sugano, Y. Nabuchi, M. Machida, and Y. Asoh, “Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane,” International Journal of Pharmaceutics, vol. 275, no. 1-2, pp. 271–278, 2004. View at: Publisher Site | Google Scholar
  25. M. Kansy, F. Senner, and K. Gubernator, “Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes,” Journal of Medicinal Chemistry, vol. 41, no. 7, pp. 1007–1010, 1998. View at: Publisher Site | Google Scholar
  26. B. J. Bennion, N. A. Be, M. W. McNerney et al., “Predicting a drug’s membrane permeability: a computational model validated with in vitro permeability assay data,” The Journal of Physical Chemistry B, vol. 121, no. 20, pp. 5228–5237, 2017. View at: Publisher Site | Google Scholar
  27. W. Qu and X. Liu, “Identification of cytochrome P450 isoforms involved in the metabolism of artocarpin and assessment of its drug-drug interaction,” Biomedical Chromatography, vol. 32, no. 4, 2018. View at: Publisher Site | Google Scholar
  28. L. Shan, G. Zhang, Z. Guo, and X. Shi, “In vitro investigation of permeability and metabolism of licoricidin,” Life Sciences, vol. 234, Article ID 116770, 2019. View at: Publisher Site | Google Scholar
  29. Y. Naritomi, S. Terashita, S. Kimura, A. Suzuki, A. Kagayama, and Y. Sugiyama, “Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans,” Drug Metabolism and Disposition, vol. 29, no. 10, pp. 1316–1324, 2001. View at: Google Scholar
  30. S. P. Singh, M. Wahajuddin, D. Tewari, K. Patel, and G. K. Jain, “Permeability determination and pharmacokinetic study of nobiletin in rat plasma and brain by validated high-performance liquid chromatography method,” Fitoterapia, vol. 82, no. 8, pp. 1206–1214, 2011. View at: Publisher Site | Google Scholar
  31. M. Jarratt, W. J. Siu, E. Yamakawa, N. Kodera, R. Pillai, and K. Smith, “Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis,” Journal of Drugs in Dermatology, vol. 12, no. 9, pp. 1010–1016, 2013. View at: Google Scholar
  32. W.-M. Zhang, R.-F. Li, J.-F. Qiu et al., “Determination of kurarinone in rat plasma by UPLC-MS/MS,” Journal of Chromatography B, vol. 986-987, pp. 31–34, 2015. View at: Publisher Site | Google Scholar
  33. J. T. Backman, M. T. Schröder, and P. J. Neuvonen, “Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine,” European Journal of Clinical Pharmacology, vol. 64, no. 1, pp. 17–24, 2008. View at: Publisher Site | Google Scholar
  34. J. J. P. Bogaards, M. Bertrand, P. Jackson et al., “Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man,” Xenobiotica, vol. 30, no. 12, pp. 1131–1152, 2000. View at: Publisher Site | Google Scholar
  35. T. Shimada, M. Mimura, K. Inoue et al., “Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans,” Archives of Toxicology, vol. 71, no. 6, pp. 401–408, 1997. View at: Publisher Site | Google Scholar
  36. X. Shi, G. Zhang, G. Ge et al., “In vitro metabolism of auriculasin and its inhibitory effects on human cytochrome P450 and UDP-glucuronosyltransferase enzymes,” Chemical Research in Toxicology, vol. 32, no. 10, pp. 2125–2134, 2019. View at: Publisher Site | Google Scholar
  37. X. Shi, G. Zhang, B. Mackie, S. Yang, J. Wang, and L. Shan, “Comparison of the in vitro metabolism of psoralidin among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes,” Journal of Chromatography B, vol. 1029-1030, pp. 145–156, 2016. View at: Publisher Site | Google Scholar
  38. H. Li, H. Zeng, D. He et al., “A new approach to examining the extraction process of zhishi and zhiqiao considering the synergistic effect of complex mixtures by pampa,” Journal of Chromatography B, vol. 1099, pp. 10–17, 2018. View at: Publisher Site | Google Scholar
  39. X. Chen, L.-S. Qiao, Y.-L. Cai, Y.-L. Zhang, and G.Y. Li, “Combination computing of support vector machine, support vector regression and molecular docking for potential cytochrome P450 1A2 inhibitors,” Chinese Journal of Chemical Physics, vol. 29, no. 5, pp. 629–634, 2016. View at: Publisher Site | Google Scholar
  40. B. Wang and S.-F. Zhou, “Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development,” Current Medicinal Chemistry, vol. 16, no. 31, pp. 4066–4218, 2009. View at: Publisher Site | Google Scholar
  41. H. Luo, C. Li, S. Zhou et al., “Pharmacophore,QSAR,and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening,” Current Pharmaceutical Biotechnology, vol. 13, no. 9, pp. 1640–1704, 2012. View at: Google Scholar
  42. Y.-Y. Zhang, Y. Liu, J.-W. Zhang et al., “Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel,” Xenobiotica, vol. 39, no. 4, pp. 283–292, 2009. View at: Publisher Site | Google Scholar

Copyright © 2020 Youfa Qin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.